Clinical trials: Primary Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
This is a double blind (sponsor unblind), repeat dose, randomized, parallel group, placebo controlled study to assess the pharmacokinetic parameters, safety, tolerability, and clinical effect of topically applied umeclidinium…
- Trial name
- NCT02563899
- Testing
- Umeclidinium, Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation
Primary Focal Hyperhidrosis, Axilla
Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis
This is a prospective, multi-center, parallel, randomized, blinded study. The study has two groups, where in one study group the subjects receive treatment for axillary hyperhidrosis (excessive underarm sweating) with the DTS-G2…
- Trial name
- DRI-UP (NCT00931359)
- Testing
- DTS-G2 System
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Miramar Labs